کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2599490 | 1133210 | 2012 | 9 صفحه PDF | دانلود رایگان |

Exposure assessment of health care workers to antineoplastic drugs (ADs) is still an open issue since new, critical, and emerging factors may put pharmacists who prepare hazardous drugs or nurses who administer anti cancer agents to an increased risk of developing adverse health effects.Overall, eight pharmacies and nine patient areas have been surveyed in this study. Wipe and pad samples were experienced during the surveillance program in four Italian health care settings. Urine samples were collected from workers handling ADs. Cyclophosphamide (CP), ifosfamide (IF), and gemcitabine (GEM) were detected in all the work environments by using a LC–MS/MS method-based capable of analysing all the three drugs simultaneously. In total, 54% of wipe samples were positive for at least one drug and 19% of pad samples were shown to be contaminated by cyclophosphamide.Pharmacies were generally more contaminated than patient areas with the exception of one site where a nurse had an acute exposure during the cleaning-up of an hazardous drug solution spill. In total, 22 urine samples collected from pharmacists and 78 urine samples from nurses had no detectable concentrations of any antineoplastic drugs. Despite the adherence to the recommended safety practices residue contamination on surfaces and floors has continued to be assessed in all the investigated sites.
► We have surveyed four hospitals different in size and work environment to assess the potentials for exposure to antineoplastic drugs.
► We examine a correlation between the levels of biomarkers and the levels of exposure.
► We evidence that surface contamination is not statistically significantly correlated with a limited number of positive urine samples.
► Increasing information will increase awareness of the potential hazards if incorrect activities are done during work-shifts.
Journal: Toxicology Letters - Volume 213, Issue 1, 13 August 2012, Pages 107–115